Armistice Capital, LLC and Steven Boyd filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of common stock in Sangamo Therapeutics, Inc. as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Armistice Capital, LLC and Steven Boyd each report 40,560,819 shares beneficially owned.
- Percent of class: The 40,560,819 shares represent 9.79% of Sangamo Therapeutics common stock.
- Voting and dispositive power: Both reporting persons report 0 shares of sole voting or sole dispositive power, and 40,560,819 shares of shared voting and shared dispositive power.
- Direct holder: According to the filing, the shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company.
- Event date: The date of the event requiring this filing is stated as September 30, 2026.
- Filing date: The statement was signed and dated November 16, 2026, by Steven Boyd as Managing Member of Armistice Capital, LLC.
Armistice Capital and Steven Boyd Disclose Shared Stake via Master Fund Structure
According to the filing, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., which is described as the direct holder of the shares. The filing states that "pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own those same securities.
The filing further notes that "the Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." Regarding the right to receive proceeds, the filing identifies the Master Fund as the entity with the right to receive dividends from, or proceeds from the sale of, the reported securities.
This is Amendment No. 2 to the Schedule 13G, filed under the Securities Exchange Act of 1934. The securities covered are Sangamo Therapeutics, Inc. common stock, par value $0.01 per share, with CUSIP number 800677106. Sangamo Therapeutics is listed with a principal office address of 501 Canal Blvd., Richmond, California 94804, according to the filing. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Armistice Capital, LLC and Steven Boyd filed Amendment No. 2 to a Schedule 13G disclosing 40,560,819 shares, or 9.79%, of Sangamo Therapeutics common stock beneficially owned as of September 30, 2026, held directly through Armistice Capital Master Fund Ltd.




Please wait processing your request...